[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-428751-105":59,"doc-detail-428751-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomics-of-sarcopenia-prevalence-and-future-risk-shared-and-distinct-pathways","PROTEOMICS OF SARCOPENIA PREVALENCE AND FUTURE RISK - SHARED AND DISTINCT PATHWAYS","","Sarcopenia is low muscle mass and function linked to systemic chronic low-grade inflammation. Using plasma proteomics from the ARIC study, researchers screened over 5,000 measures to find changes that precede sarcopenia onset and to support therapy development and risk stratification. Sarcopenia was defined by weak grip strength and slow walking speed, quantifying aptamer profiles for 4,000+ proteins. Candidate proteins showed distinct and shared associations across prevalence and incidence, with pathway enrichment and prediction performance reported by AUC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomics-of-sarcopenia-prevalence-and-future-risk-shared-and-distinct-pathways/428751/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomics-of-sarcopenia-prevalence-and-future-risk-shared-and-distinct-pathways/428751.png","ImageObject",300,407,{"name":92,"@type":93},"SANS","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was sarcopenia defined in this study?","Question",{"text":112,"@type":113},"Sarcopenia was defined using the SDOC criteria of weak grip strength and slow walking speed during ARIC visits 5 (2011–2013) and visit 6 (2016–2017).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proteomic approach was used to measure proteins?",{"text":117,"@type":113},"The study quantified aptamer measures for 4,000+ unique proteins from visit 5 plasma using the SomaLogic platform.",{"name":119,"@type":110,"acceptedAnswer":120},"Which proteins and pathways were linked to sarcopenia?",{"text":121,"@type":113},"Proteins associated with incidence included PXDN, TIMP4, RNASE1, GDF15, SVEP1, THBS2, ANGPT2, and EGFR, all also related to prevalence. Prevalence-associated proteins showed enrichment in antigen processing and presentation, apoptosis, carbohydrate digestion and absorption, and Fanconi anemia pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},428751,1790792215,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},962090760505,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Innovation in Aging, 2025, Vol. 9, No. S2 361  \nAbstract citation ID: igaf122.1221  \nPROTEOMICS OF SARCOPENIA PREVALENCE AND FUTURE RISK: SHARED AND DISTINCT PATHWAYS  \nHubert Leo1, Aditya Surapaneni1, Shoshana Ballew1, Jordan Weiss2, Morgan Grams1, Marcus Goncalves1, and Josef Coresh1, 1. New York University, New York, New York, United States, 2. NYU Grossman School of Medicine, New York, New York, United States  \nSarcopenia is a state of low muscle mass and function that is known to be related to systemic, low-grade, chronic inflammation. We screened over 5,000 proteomic measures to identify changes preceding sarcopenia incidence to inform development of therapies and risk stratification. We defined sarcopenia using the SDOC definition of weak grip strength and slow walking speed at the 2011–2013 (Visit 5, N = 6,538, mean (SD) age 76  \n(5)) and 2016-2017 (visit 6, N =4,003) visits ofthe Atherosclerosis Risk in Communities (ARIC) study. We quantified aptamer measures of over 4,000 unique proteins from Visit 5 plasma using the SomaLogic platform. Sarcopenia was present in 665 participants (11.3%) at baseline and new incident cases developed in  \n391 (9.8%) by Visit 6. Among the 5,272 aptamers tested, 114 were associated with sarcopenia prevalence and 9 were associated with sarcopenia incidence after adjustment for age, sex, eGFRcr-cys, and multiple comparisons (Bonferroni p \u003C 9.5E-6) . The proteins associated with sarcopenia incidence (PXDN, TIMP4, RNASE1, GDF15, SVEP1, THBS2, SVEP1, ANGPT2, EGFR) were all associated with sarcopenia prevalence (eight atp \u003C 4E-6; TIMP4 p = 1E-4). Pathway analysis on proteins associated with sarcopenia prevalence showed enrichment for Antigen Processing and Presentation, Apoptosis, Carbohydrate Digestion and Absorption, and Fanconi anemia pathways. Sarcopenia incidence prediction had an AUC of 0.713 for nine proteins, 0.709 for age and clinical factors, and 0.749 combined. This is the largest proteomic screen of incident sarcopenia and provides new insights into proteomic alterations that both precede and predict risk of sarcopenia.","cbCaijN8UfzATX8Y","https://ap.wps.com/l/cbCaijN8UfzATX8Y","pdf",365181,"English","# Abstract\n## Study design and sarcopenia definition\n## Proteomic screening and protein associations\n## Pathway enrichment\n## Risk prediction performance","[{\"question\":\"How was sarcopenia defined in this study?\",\"answer\":\"Sarcopenia was defined using the SDOC criteria of weak grip strength and slow walking speed during ARIC visits 5 (2011–2013) and visit 6 (2016–2017).\"},{\"question\":\"What proteomic approach was used to measure proteins?\",\"answer\":\"The study quantified aptamer measures for 4,000+ unique proteins from visit 5 plasma using the SomaLogic platform.\"},{\"question\":\"Which proteins and pathways were linked to sarcopenia?\",\"answer\":\"Proteins associated with incidence included PXDN, TIMP4, RNASE1, GDF15, SVEP1, THBS2, ANGPT2, and EGFR, all also related to prevalence. Prevalence-associated proteins showed enrichment in antigen processing and presentation, apoptosis, carbohydrate digestion and absorption, and Fanconi anemia pathways.\"}]","PROTEOMICS OF SARCOPENIA PREVALENCE AND FUTURE RISK - SHARED AND DISTINCT PATHWAYS | PDF",1790647563]